Publication Name	World Journal of Gastroenterology
Manuscript ID	21087
Country	Italy

Received	2015-06-30 12:02
Peer-Review Started	2015-07-03 08:28
To Make the First Decision	2015-08-31 08:54
Return for Revision	2015-08-31 16:33
Revised	2015-09-03 01:52
Second Decision	2015-10-12 09:04
Accepted by Journal Editor-in-Chief	2015-10-14 08:47
Accepted by Company Editor-in-Chief	2015-10-20 09:54
Articles in Press	2015-10-20 09:54
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-11-03 10:08
Publish the Manuscript Online	2015-11-18 12:39

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications
Manuscript Source	Invited Manuscript
All Author List	Francesca Romana Ponziani, Viviana Gerardi, Silvia Pecere, Francesca D’Aversa, Loris Lopetuso, Maria Assunta Zocco, Maurizio Pompili and Antonio Gasbarrini
Funding Agency and Grant Number
Corresponding Author	Silvia Pecere, MD, Internal Medicine and Gastroenterology, Agostino Gemelli Hospital, via Moscati 31, 00168 Rome, Italy. silvia.pecere@gmail.com
Key Words	Liver cirrhosis; Gut microbiota; Rifaximin; Hepatic encephalopathy; Spontaneous bacterial peritonitis; Ascites; Endotoxemia; Thrombocytopenia
Core Tip	Advanced liver disease is characterized by intestinal dysbiosis, which has been involved in the pathogenesis of complications. Rifaximin is able to improve cognitive tests and practical abilities, to reduce the risk of hepatic encephalopathy (he) recurrence and the number of he-related hospitalizations. Rifaximin efficacy seems not associated with major changes in gut bacteria composition but rather with a shift in the microbiome functionality. Rifaximin is useful in the prevention of spontaneous bacterial peritonitis in patients with ascites. Rifaximin reduces endotoxemia and has beneficial effects on cirrhotic patients hemo-dynamics, reducing the incidence of complications related to portal hypertension.
Publish Date	2015-11-18 12:39
Citation	Ponziani FR, Gerardi V, Pecere S, D’Aversa F, Lopetuso L, Zocco MA, Pompili M, Gasbarrini A. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol 2015; 21(43): 12322-12333
URL	http://www.wjgnet.com/1007-9327/full/v21/i43/12322.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i43.12322

Full Article (PDF)	WJG-21-12322.pdf
Full Article (Word)	WJG-21-12322.doc
Manuscript File	21087-Review.docx
Answering Reviewers	21087-Answering reviewers.pdf
Audio Core Tip	21087-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	21087-Conflict of interest statement.pdf
Copyright License Agreement	21087-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	21087-Language certificate.pdf
Peer-review Report	21087-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	21087-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	21087-Scientific misconduct check.pdf
Scientific Editor Work List	21087-Scientific editor work list.pdf